BioView, ScreenCell Partner to Develop CTC Analysis Technology | GenomeWeb

NEW YORK (GenomeWeb News) – BioView and ScreenCell today announced a deal to develop a circulating tumor cell analysis technology.

The agreement seeks to combine ScreenCell's technology for isolating rare cells that may have prognostic and predictive value in cancer and BioView's scanning platform, which provides automated imaging and analysis solutions for rare cell and circulating tumor cell detection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.